Amoeba S.A.

Historical price data

Amoeba S.A. is a clinical-stage biotech focused on commercializing biological products for agriculture and industrial water treatment. Its core achievement is the development of a proprietary platform based on *Willaertia magna*, leading to its lead agricultural candidate, NomaT™, which is advancing through EU regulatory processes. The company's strategy is to secure key regulatory approvals and establish commercial partnerships to penetrate the large markets for sustainable crop protection and non-chemical water treatment. Amoeba operates as a publicly listed R&D entity, funded through equity offerings, to achieve these milestones.

Platform based on the predatory bacterium *Willaertia magna* C2c Maky, producing a lysate that physically disrupts bacterial cell membranes, offering a resistance-breaking mode of action for biocontrol and biocide applications.

In agriculture, Amoeba competes with large agrochemical firms expanding into biologics and specialized biocontrol companies, differentiating via its physical mode of action. In industrial water, it must compete against dominant chemical suppliers, offering a biological alternative for biofilm and legionella control.